I do not concur, as the individual components of t
Post# of 148187
That would be like assessing SAEs vs placebo for the patients who died in day 8 of a 14 day trial.
As well, Dr. Pourhassan has demonstrated that he does not consistently utilize verbiage expected when discussing clinical trials.
He defers to Dr. Kelly in the conference calls, but goes it alone on Proactive.
As well, he has been attempting, with mixed success, to constrain (IMO) his elation since announcement of good results on July 17 after data locked and unblinded.
Just my observations. Time will shortly tell.